TORL BioTherapeutics
PrivateLast Round
Series C
Oct 7, 2025
Total Funding Raised
$461.9M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
TORL BioTherapeutics is a biopharmaceutical company that develops antibody-drug conjugates and monoclonal antibodies for the treatment of various cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TORL BioTherapeutics Comparables
Compare TORL BioTherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Gilead Sciences | 87% | |
| Sutro Biopharma Inc | 80% | |
| Genmab A/S | 79% |
TORL BioTherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 7, 2025 | ||||
| Series B Extension | Apr 10, 2024 | ||||
| Series B | Apr 13, 2023 |
Key People
Founding team and executive leadership
TORL BioTherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series B Extension |
| Vertex Ventures HC | Series B, Series B Extension |
| Perceptive Advisors | Series B, Series B Extension |
| Xontogeny | Series B, Series B Extension |
| TD Securities | Series B |
| Blue Owl Capital | Series B, Series B Extension |
| Deep Track Capital | Series B, Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 83% MoM, reaching 6.8K.
- Oct 7, 2025
$96M round completed.
TORL BioTherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about TORL BioTherapeutics's valuation, stock price, and market status.
Is TORL BioTherapeutics a public or private company?
TORL BioTherapeutics is a private company.
What is the current stock price of TORL BioTherapeutics?
TORL BioTherapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is TORL BioTherapeutics worth (valuation)?
Valuation information for TORL BioTherapeutics is not publicly available.
Can I buy TORL BioTherapeutics stock?
TORL BioTherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was TORL BioTherapeutics's last funding round?
TORL BioTherapeutics's most recent funding round was Series C on October 7, 2025.
Who are the main investors in TORL BioTherapeutics?
Key investors in TORL BioTherapeutics include Deep Track Capital, Goldman Sachs Asset Management.
Will TORL BioTherapeutics IPO soon?
No public IPO plans have been announced for TORL BioTherapeutics.
How can I track TORL BioTherapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor TORL BioTherapeutics's secondary market activity and sign up for updates.